ERBB2 and breast carcinoma: Currently, the monoclonal antibodies trastuzumab (Herceptin), pertuzumab (Perjeta), and trastuzumab emtansine (T-DM1, Kadcyla) have FDA approval for treatment of HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings [9].